Related Experiment Video
Updated: Jul 6, 2026
08:34
Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
Methods of telomerase inhibition
Lucy G Andrews1, Trygve O Tollefsbol
1Department of Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Methods in Molecular Biology (Clifton, N.J.)
|March 29, 2008
Summary
Telomerase inhibition is a promising anticancer strategy. Research focuses on targeting telomerase components like telomerase reverse transcriptase (TERT) and telomerase RNA (TR), or associated proteins such as tankyrase, to combat cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Telomerase is crucial for cellular immortality.
- It is highly expressed in most cancer cells but not in normal cells.
- This makes telomerase a significant target for cancer therapy.
Purpose of the Study:
- To summarize recent advancements in telomerase inhibition strategies.
- To explore different approaches for targeting telomerase as an anticancer strategy.
Main Methods:
- Focusing on inhibiting the telomerase ribonucleoprotein holoenzyme.
- Targeting the telomerase reverse transcriptase (TERT) catalytic subunit.
- Targeting the telomerase RNA (TR) component.
- Developing protocols to inhibit associated proteins like tankyrase.
Main Results:
- Several methods for telomerase inhibition have been developed.
- These methods target key components of the telomerase complex.
- Advances include targeting TERT, TR, and associated proteins.
Conclusions:
- Telomerase inhibition represents a viable anticancer approach.
- Targeting telomerase components (TERT, TR) and associated proteins (tankyrase) are key strategies.
- Continued research in this area holds significant therapeutic potential.
Related Concept Videos
02:41Telomeres and Telomerase
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
02:41Telomeres and Telomerase
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
02:15Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.